Clara Lee

Clara Lee

Auto-generated profile, based on publicly available information

Clara Lee

Monash University School of Biological Sciences , 25 Rainforest Walk, Clayton, VIC 3800 , Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
RSRita Serrano
Rita Serrano
CLClara Lee
Clara Lee
ADAlon Moshe Douek
Alon Moshe Douek
Jan KaslinJan Kaslin
Jan Kaslin
RBRobert James Bryson-Richardson
Robert James Bryson-Richardson
Tamar SztalTamar Sztal
Tamar Sztal
Cyclin-dependent kinase-like-5 (CDKL5) deficiency disorder (CDD) is a severe X-linked neurodegenerative disease characterised by early-onset epileptic seizures, low muscle tone, progressive intellectual disability and severe motor function. CDD affects ∼1 in 60,000 live births, with many patients experiencing a reduced quality of life due to the severity of their neurological symptoms and functional impairment. There are no effective therapies for CDD, with current treatments focusing on improving symptoms rather than addressing the underlying causes of the disorder. Zebrafish offer many unique advantages for high-throughput preclinical evaluation of potential therapies for neurological diseases, including CDD. In particular, the large number of offspring produced, together with the possibilities for in vivo imaging and genetic manipulation, allows for the detailed assessment of disease pathogenesis and therapeutic discovery. We have characterised a loss-of-function zebrafish model for CDD, containing a nonsense mutation in cdkl5. cdkl5 mutant zebrafish display defects in neuronal patterning, seizures, microcephaly, and reduced muscle function caused by impaired muscle innervation. This study provides a powerful vertebrate model for investigating CDD disease pathophysiology and allowing high-throughput screening for effective therapies. This article has an associated First Person interview with the first author of the paper.

15 April 2024 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
EMEmily A McKaige
Emily A McKaige
CLClara Lee
Clara Lee
VCVanessa Calcinotto
Vanessa Calcinotto
SGSaveen Giri
Saveen Giri
SCSimon Crawford
Simon Crawford
RBRobert James Bryson-Richardson
Robert James Bryson-Richardson
Mutations in DNAJB6 are a well-established cause of limb girdle muscular dystrophy type D1 (LGMD D1). Patients with LGMD D1 develop progressive muscle weakness with histology showing fibre damage, autophagic vacuoles, and aggregates. Whilst there are many reports of LGMD D1 patients, the role of DNAJB6 in the muscle is still unclear. In this study, we developed a loss of function zebrafish model in order to investigate the role of Dnajb6. Using a double dnajb6a and dnajb6b mutant model, we show that loss of Dnajb6 leads to a late onset muscle weakness. Interestingly, we find that adult fish lacking Dnajb6 do not have autophagy or myofibril defects, however, they do show mitochondrial changes and damage. This study demonstrates that loss of Dnajb6 causes mitochondrial defects and suggests that this contributes to muscle weakness in LGMD D1. These findings expand our knowledge of the role of Dnajb6 in the muscle and provides a model to screen novel therapies for LGMD D1.

14 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLee B Miles
Lee B Miles
VCVanessa Calcinotto
Vanessa Calcinotto
CSCarmen Sonntag
Carmen Sonntag
CLClara Lee
Clara Lee
RBRobert James Bryson-Richardson
Robert James Bryson-Richardson
We developed a highly efficient targeted insertional mutagenesis system, CRIMP, and an associated plasmid toolkit, CRIMPkit, that disrupts native gene expression by inducing complete transcriptional termination to produce null mutant alleles without inducing genetic compensation. The CRIMPkit contains over 30 ready-to-use plasmid vectors allowing easy and complete mutagenesis of any gene in any reading frame without requiring custom sequences, modification, or subcloning, and also provides a fluorescent readout of successfully mutagenised fish.

9 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
RSRita J. Serrano
Rita J. Serrano
CLClara Lee
Clara Lee
RBRobert James Bryson-Richardson
Robert James Bryson-Richardson
Tamar SztalTamar Sztal
Tamar Sztal
Cyclin-dependent kinase-like-5 (CDKL5) Deficiency Disorder (CDD) is a severe X-linked neurodegenerative disease characterized by early-onset epileptic seizures, low muscle tone, progressive intellectual disability, severe motor function and visual impairment. CDD affects approximately 1 in 60,000 live births with many patients dying by early adulthood. For many patients, quality of life is significantly reduced due to the severity of their neurological symptoms and functional impairment. There are no effective therapies for CDD with current treatments focusing on improving symptoms rather than addressing the underlying causes of the disorder. Zebrafish offer a number of unique advantages for high-throughput pre-clinical evaluation of potential therapies for human neurological diseases including CDD. In particular, the large number of zebrafish that can be produced, together with the possibilities for in vivo imaging and genetic manipulation, allows for the detailed assessment of disease pathogenesis and therapeutic discovery. We have characterised a loss of function zebrafish model for CDD, containing a nonsense mutation in cdkl5 . cdkl5 mutant zebrafish display defects in neuronal patterning, microcephaly, and reduced muscle function caused by impaired muscle innervation. This study provides a powerful vertebrate model to investigate CDD disease pathophysiology and allow high-throughput screening for effective therapies.